FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101494539> ?p ?o ?g. }

• W2101494539 endingPage "1322" @default.
• W2101494539 startingPage "1314" @default.
• W2101494539 abstract "We summarized results in 38 consecutive patients (median age=56 years) with hematologic malignancies (n=35), aplastic anemia (n=2), or renal cell carcinoma (n=1), who underwent salvage hematopoietic cell transplantation (HCT) for allograft rejection. In 14 patients, the original donors were used for salvage HCT, and, in 24 cases, different donors were used. Conditioning for salvage HCT consisted of fludarabine (Flu) and either 3 or 4 Gy total body irradiation (TBI). Sustained engraftment was achieved in 33 patients (87%). Grafts were rejected in 5 patients (13%), 4 of whom had myelofibrosis. With a median follow-up of 2 years (range: 0.3 to 7.8 years), the 2- and 4-year estimated survivals were 49% and 42%, respectively. The 2-year relapse rate and nonrelapse mortality (NRM) were 36% and 24%, respectively. The 2-year cumulative incidences of grades II-IV acute and moderate-severe chronic graft-versus-host disease (aGVHD, cGVHD) were 42% and 41%, respectively. In this cohort, TBI dose, grafts from original versus different donors, related versus unrelated donors, and HCT comorbidity scores did not have an impact on outcomes. We concluded that graft rejection after allogeneic HCT could be overcome by salvage transplantation using conditioning with Flu and low-dose TBI. We summarized results in 38 consecutive patients (median age=56 years) with hematologic malignancies (n=35), aplastic anemia (n=2), or renal cell carcinoma (n=1), who underwent salvage hematopoietic cell transplantation (HCT) for allograft rejection. In 14 patients, the original donors were used for salvage HCT, and, in 24 cases, different donors were used. Conditioning for salvage HCT consisted of fludarabine (Flu) and either 3 or 4 Gy total body irradiation (TBI). Sustained engraftment was achieved in 33 patients (87%). Grafts were rejected in 5 patients (13%), 4 of whom had myelofibrosis. With a median follow-up of 2 years (range: 0.3 to 7.8 years), the 2- and 4-year estimated survivals were 49% and 42%, respectively. The 2-year relapse rate and nonrelapse mortality (NRM) were 36% and 24%, respectively. The 2-year cumulative incidences of grades II-IV acute and moderate-severe chronic graft-versus-host disease (aGVHD, cGVHD) were 42% and 41%, respectively. In this cohort, TBI dose, grafts from original versus different donors, related versus unrelated donors, and HCT comorbidity scores did not have an impact on outcomes. We concluded that graft rejection after allogeneic HCT could be overcome by salvage transplantation using conditioning with Flu and low-dose TBI." @default.
• W2101494539 created "2016-06-24" @default.
• W2101494539 creator A5005492422 @default.
• W2101494539 creator A5011099910 @default.
• W2101494539 creator A5012590130 @default.
• W2101494539 creator A5016684714 @default.
• W2101494539 creator A5055821837 @default.
• W2101494539 creator A5067443773 @default.
• W2101494539 creator A5069648775 @default.
• W2101494539 creator A5076914241 @default.
• W2101494539 creator A5077236629 @default.
• W2101494539 creator A5084915025 @default.
• W2101494539 creator A5085787488 @default.
• W2101494539 creator A5087069801 @default.
• W2101494539 date "2009-10-01" @default.
• W2101494539 modified "2023-10-02" @default.
• W2101494539 title "Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts" @default.
• W2101494539 cites W1508187469 @default.
• W2101494539 cites W1973617793 @default.
• W2101494539 cites W1998790877 @default.
• W2101494539 cites W1999536033 @default.
• W2101494539 cites W2000454853 @default.
• W2101494539 cites W2025178508 @default.
• W2101494539 cites W2025794210 @default.
• W2101494539 cites W2026625631 @default.
• W2101494539 cites W2036282703 @default.
• W2101494539 cites W2046378281 @default.
• W2101494539 cites W2061277935 @default.
• W2101494539 cites W2070028596 @default.
• W2101494539 cites W2070091170 @default.
• W2101494539 cites W2078782557 @default.
• W2101494539 cites W2104711659 @default.
• W2101494539 cites W2115412294 @default.
• W2101494539 cites W2127036836 @default.
• W2101494539 cites W2128185637 @default.
• W2101494539 cites W2128812336 @default.
• W2101494539 cites W2158682205 @default.
• W2101494539 cites W2165628873 @default.
• W2101494539 cites W2242587738 @default.
• W2101494539 cites W2257559310 @default.
• W2101494539 cites W2268207673 @default.
• W2101494539 cites W2317117822 @default.
• W2101494539 cites W2337969406 @default.
• W2101494539 cites W2411653119 @default.
• W2101494539 cites W2584695957 @default.
• W2101494539 cites W2618073389 @default.
• W2101494539 cites W296347676 @default.
• W2101494539 cites W5387557 @default.
• W2101494539 doi "https://doi.org/10.1016/j.bbmt.2009.06.011" @default.
• W2101494539 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2757150" @default.
• W2101494539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19747640" @default.
• W2101494539 hasPublicationYear "2009" @default.
• W2101494539 type Work @default.
• W2101494539 sameAs 2101494539 @default.
• W2101494539 citedByCount "29" @default.
• W2101494539 countsByYear W21014945392012 @default.
• W2101494539 countsByYear W21014945392013 @default.
• W2101494539 countsByYear W21014945392014 @default.
• W2101494539 countsByYear W21014945392015 @default.
• W2101494539 countsByYear W21014945392016 @default.
• W2101494539 countsByYear W21014945392017 @default.
• W2101494539 countsByYear W21014945392018 @default.
• W2101494539 countsByYear W21014945392020 @default.
• W2101494539 countsByYear W21014945392021 @default.
• W2101494539 countsByYear W21014945392022 @default.
• W2101494539 countsByYear W21014945392023 @default.
• W2101494539 crossrefType "journal-article" @default.
• W2101494539 hasAuthorship W2101494539A5005492422 @default.
• W2101494539 hasAuthorship W2101494539A5011099910 @default.
• W2101494539 hasAuthorship W2101494539A5012590130 @default.
• W2101494539 hasAuthorship W2101494539A5016684714 @default.
• W2101494539 hasAuthorship W2101494539A5055821837 @default.
• W2101494539 hasAuthorship W2101494539A5067443773 @default.
• W2101494539 hasAuthorship W2101494539A5069648775 @default.
• W2101494539 hasAuthorship W2101494539A5076914241 @default.
• W2101494539 hasAuthorship W2101494539A5077236629 @default.
• W2101494539 hasAuthorship W2101494539A5084915025 @default.
• W2101494539 hasAuthorship W2101494539A5085787488 @default.
• W2101494539 hasAuthorship W2101494539A5087069801 @default.
• W2101494539 hasBestOaLocation W21014945391 @default.
• W2101494539 hasConcept C126322002 @default.
• W2101494539 hasConcept C126894567 @default.
• W2101494539 hasConcept C141071460 @default.
• W2101494539 hasConcept C2776694085 @default.
• W2101494539 hasConcept C2776755627 @default.
• W2101494539 hasConcept C2777408962 @default.
• W2101494539 hasConcept C2778248108 @default.
• W2101494539 hasConcept C2778880498 @default.
• W2101494539 hasConcept C2779263901 @default.
• W2101494539 hasConcept C2780007613 @default.
• W2101494539 hasConcept C2780775027 @default.
• W2101494539 hasConcept C2781440808 @default.
• W2101494539 hasConcept C2911091166 @default.
• W2101494539 hasConcept C71924100 @default.
• W2101494539 hasConcept C90924648 @default.
• W2101494539 hasConceptScore W2101494539C126322002 @default.
• W2101494539 hasConceptScore W2101494539C126894567 @default.
• W2101494539 hasConceptScore W2101494539C141071460 @default.

• next